No price history available.
Key financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INRm | 10,800 | 12,186 | 15,037 | 16,401 | 17,882 | 16,649 | 18,453 | N/A | N/A |
| Operating profit | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | INRm | 241 | 930 | 1,548 | 1,423 | 985 | -737 | -987 | N/A | N/A |
| EPS reported | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Indoco Remedies Limited, an Indian pharmaceutical company founded in Mumbai in 1945 (originally known as Indo Continental Trading Company), operates globally, manufacturing and distributing a broad spectrum of finished drug formulations and active pharmaceutical ingredients (APIs). The company's extensive product portfolio addresses diverse therapeutic areas: Respiratory conditions: with offerings like Karvol Plus, Febrex Plus, and Tuspel. Oral and dental care (stomatologicals): including Sensodent-K, Sensoform Toothpaste, the Rexidin series, and Snowdent. Gastrointestinal ailments: featuring products such as Carmicide, Cyclopam, and Nosic. Pain relief/analgesics: exemplified by Lignox and T-lac. Ophthalmic and otic solutions: comprising items like Renolen, Dexoren – S, and the Mofloren range. Vitamins, minerals, and nutritional supplements: such as Methycal, MCBM DHA, and Apispur. Urological treatments: including Carmicide and Cital. Dermatological preparations: like Cloben G and Scabex. Anti-infective agents: represented by ATM. Blood-related therapies: such as Hemsyl. Gynecological health products: including MCBM 69 and D Chiro. Anti-haemorrhoidal treatments: with Spear. Beyond its pharmaceutical manufacturing, Indoco Remedies provides comprehensive analytical services. These include impurity profiling, particle size analysis, heavy metal analysis, polymorphism studies, compatibility and stability assessments (like extractables/leachables and lyophilization), and advanced chromatographic method development and validation. Furthermore, the company offers a suite of engineering and project management services. This covers architectural and structural design, mechanical and electrical engineering, lighting solutions, control system integration, piping design, data transfer systems, and holistic project and construction management for process facilities. Indoco Remedies serves a wide range of medical professionals, from general practitioners and pediatricians to specialized consultants like dentists, cardiologists, diabetologists, endocrinologists, gynaecologists, and ophthalmologists.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Indoco Remedies Limited (INDOCO.NS)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Indoco Remedies Limited, an Indian pharmaceutical company founded in Mumbai in 1945 (originally known as Indo Continental Trading Company), operates globally, manufacturing and distributing a broad spectrum of finished drug formulations and active pharmaceutical ingredients (APIs). The company's extensive product portfolio addresses diverse therapeutic areas: Respiratory conditions: with offerings like Karvol Plus, Febrex Plus, and Tuspel. Oral and dental care (stomatologicals): including Sensodent-K, Sensoform Toothpaste, the Rexidin series, and Snowdent. Gastrointestinal ailments: featuring products such as Carmicide, Cyclopam, and Nosic. Pain relief/analgesics: exemplified by Lignox and T-lac. Ophthalmic and otic solutions: comprising items like Renolen, Dexoren – S, and the Mofloren range. Vitamins, minerals, and nutritional supplements: such as Methycal, MCBM DHA, and Apispur. Urological treatments: including Carmicide and Cital. Dermatological preparations: like Cloben G and Scabex. Anti-infective agents: represented by ATM. Blood-related therapies: such as Hemsyl. Gynecological health products: including MCBM 69 and D Chiro. Anti-haemorrhoidal treatments: with Spear. Beyond its pharmaceutical manufacturing, Indoco Remedies provides comprehensive analytical services. These include impurity profiling, particle size analysis, heavy metal analysis, polymorphism studies, compatibility and stability assessments (like extractables/leachables and lyophilization), and advanced chromatographic method development and validation. Furthermore, the company offers a suite of engineering and project management services. This covers architectural and structural design, mechanical and electrical engineering, lighting solutions, control system integration, piping design, data transfer systems, and holistic project and construction management for process facilities. Indoco Remedies serves a wide range of medical professionals, from general practitioners and pediatricians to specialized consultants like dentists, cardiologists, diabetologists, endocrinologists, gynaecologists, and ophthalmologists.